BioXell confirms strong potential of Elocalcitol

19-Oct-2007

At its second annual R&D Day in Zurich, BioXell presented further analysis of its Phase IIb trial data in benign prostatic hyperplasia (BPH), confirming that Elocalcitol has strong potential to become a new first-line monotherapy for BPH. Current BPH first-line therapies consist of combinations of drugs treating disease progression and symptoms, all of which may be associated with significant side effects. Elocalcitol, at an optimal dosage of 150 mcg, has been shown to have the following competitive profile:

- Efficacy on key parameters of BPH disease progression: arrest of prostate growth, improvement in maximum urinary flow rate (Qmax), and prevention of both Acute Urinary Retention (AUR) and the need for surgery

- Efficacy in treating lower urinary tract symptoms (LUTS): improvement on urgency, frequency and nocturia

- Safety profile comparable to or better than placebo, with lower incidence of sexual side effects; extremely well tolerated and accepted by patients

The new data for Elocalcitol are consistent with the positive effect on LUTS already observed in a Phase IIa clinical trial in Overactive Bladder (OAB). Based on on-going consultations with its advisory boards and key opinion leaders, the Company will define its Phase III development plan for Elocalcitol in BPH.

Other news from the department research and development

Most read news

More news from our other portals

So close that even
molecules turn red...